Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis

Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms focuSSced
  • Sponsors Chugai Pharmaceutical; Roche

Most Recent Events

  • 31 Aug 2023 Results assessing biomarkers of fibrosis, inflammation, and extracellular matrix , published in the Clinical Immunology
  • 19 May 2021 Results of a post hoc analysis assessing the safety and efficacy of a subset of patients who had Systemic Sclerosis Interstitial Lung Disease at baseline, as evidenced by high-resolution computed tomography presented at the 117th International Conference of the American Thoracic Society
  • 19 May 2021 Results (n=136) of post-hoc analyses assessing the SSc-ILD at baseline, high-resolution computed tomography, Lung function assessed by change from baseline to week 48 in absolute forced vital capacity and percent-predicted forced vital capacity in patients with SSc-ILD, presented at the 117th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top